** Drug developer Allakos' ALLK.O shares fall 72.7% to 33 cents premarket
** Co says its experimental drug, AK006, did not show clinical benefit in an early-stage trial testing it in patients with chronic spontaneous urticaria — a skin condition that causes itching and hives
** As a result, the company has decided to discontinue further clinical development of AK006
** Co also plans to reduce its workforce by 75%
** Co plans to retain about 15 employees to explore strategic alternatives, maintain compliance with regulatory and financial reporting requirements, and wind-down the early-stage trial
** Estimates it will have cash, cash equivalents and investments in a range of approximately $35 mln to $40 mln at June 30, 2025
** Stock had fallen 55.7% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。